Zobrazeno 1 - 10
of 85
pro vyhledávání: ''
Publikováno v:
Molecular Cancer Research. 18:835-846
Through the use of an unbiased, genome-scale CRISPR modifier screen, we identified NF1 suppression as a mechanism of resistance to EGFR inhibition in NRAS/KRAS/BRAFV600-wild-type colorectal cancer cells. Reduced NF1 expression permitted sustained sig
Autor:
Helmout Modjtahedi, Soozana Puvanenthiran, Sharadah Essapen, Izhar Bagwan, Alan M. Seddon, Said Abdullah Khelwatty
Publikováno v:
Cancer Research. 81:350-350
Background: Overexpression of the EGFR is common in patients with a wide range of cancers and the EGFR is an important target for therapy with monoclonal antibodies (mAbs) based drugs. Of these, cetuximab and panitumumab have been approved for the tr
Autor:
Vishnu C. Damalanka, James W. Janetka, Lidija Klampfer, Robert J. Coffey, Galina Bogatcheva, Ramona Graves-Deal, Bhuminder Singh
Publikováno v:
Cancer Research. 81:1084-1084
Using a novel 3D culture system, we previously showed that activation of receptor tyrosine kinases (RTKs) MET and RON contributed to cetuximab resistance in colorectal cancer (CRC) cells. CC derived from HCA-7 cells were sensitive to cetuximab, where
Autor:
Chun Gong, Fei-jiao Ge, Ming Ni, Jianming Xu, Rongrui Liu, Chuanhua Zhao, Jun-Yan Gu, Yan Wang, Zhaoli Tan, Ru Jia, Mansheng Li, Shuji Ogino, He-Fei Wang, Yang Jin, Yunping Zhu, Li Lin, Youliang Wang, Yu Ling Chen, Tao Liu, Zhi Rong Qian
Publikováno v:
Clinical Cancer Research. 23:4602-4616
Purpose: Mutations in KRAS are considered to be the main drivers of acquired resistance to epidermal growth factor receptor (EGFR) blockade in patients with metastatic colorectal cancer (mCRC). However, the potential role of other genes downstream of
Autor:
Takatsugu Okegawa, Shuta Tomida, Suguru Hamada, Kikuo Nutahara, Hidetoshi Hayashi, Kazuko Sakai, Masato Terashima, Kazuto Nishio, Yu Nakamura, Yosuke Togashi, Yoshihiko Fujita, Eri Banno, Marco A. De Velasco, Hirokazu Nakahara
Publikováno v:
Molecular Cancer Therapeutics. 15:1988-1997
The prognosis for patients with advanced esophageal or head-and-neck squamous cell carcinoma (ESCC or HNSCC) remains poor, and the identification of additional oncogenes and their inhibitors is needed. In this study, we evaluated the sensitivities of
Autor:
Edward C. Stites
Publikováno v:
Cancer Research. 75:B1-58
Emerging data suggest different activating Ras mutants may have different biological behaviors. The most striking example may be in colon cancer, where activating KRAS mutations generally indicate a lack of benefit to treatment with cetuximab, with t
Autor:
Luigi Formisano, Erika Martinelli, Matilde Lambiase, Francesca Fenizia, Roberto Bianco, Floriana Morgillo, Fortunato Ciardiello, Giulia Martini, Donata Vitagliano, Teresa Troiani, Claudia Cardone, Nicola Normanno, Davide Ciardiello, Stefania Napolitano
Publikováno v:
Clinical Cancer Research. 21:4153-4164
Purpose: The use of cetuximab in the treatment of metastatic colorectal cancer is limited by development of resistance. Experimental Design: We have investigated in three models of highly epidermal growth factor receptor (EGFR)–dependent colorectal
Autor:
Vishnu C. Damalanka, James W. Janetka, Robert J. Coffey, Lidija Klampfer, Bhuminder Singh, Galina Bogatcheva, Ramona Graves-Deal
Publikováno v:
Cancer Research. 80:3451-3451
Using 3D type I collagen cultures of human colorectal cancer (CRC) cell line HCA-7 derivatives (CC, SC, CC-CR), we previously identified that activation of receptor tyrosine kinases (RTKs) MET and RON contributed to resistance to anti-EGFR monoclonal
Autor:
Lars D. Engstrom, Peter Olson, James G. Christensen, Lauren Hargis, Andrew Calinisan, David Briere, Matthew A. Marx, Ruth Aranda, Jill Hallin
Publikováno v:
Cancer Research. 80:LB-098
The ability to develop effective therapies for KRAS mutant cancers has remained elusive despite decades of research. MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor presently under evaluation in clinical trials. MRTX849
Autor:
Maria Luana Poeta, Emanuela Signori, Jesus Garcia-Foncillas, Caterina Fusilli, Luisa Loiacono, Tommaso Mazza, Giuseppe Lamorte, Vito Michele Fazio, Mariangela De Robertis, Massimo Sanchez, Angelo L. Vescovi, Luigi Marchionni
Publikováno v:
Cancer Research. 80:4296-4296
Tumor heterogeneity and the presence of stem-like cells have been identified as key features for resistance to anticancer treatments including targeted therapy. The Eph receptors comprise a large family of receptor tyrosine kinases that marks stem-li